Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
H Nabi, O Hendricks, DV Jensen, AG Loft… - RMD open, 2022 - rmdopen.bmj.com
Objective Successful uptake of biosimilars in rheumatology is limited by lack of real-world
evidence regarding effectiveness of biosimilar-to-biosimilar switching. We investigated …
evidence regarding effectiveness of biosimilar-to-biosimilar switching. We investigated …
[CITATION][C] Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory Arthritis Followed in the Danish DANBIO Registry: Switch from …
H Nabi, B Glintborg, AG Loft, O Hendricks, JK Pedersen… - 2021 - vbn.aau.dk
Biosimilar to Biosimilar Infliximab Switching in Real-world Patients with Inflammatory
Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 …
Arthritis Followed in the Danish DANBIO Registry: Switch from Originator Infliximab to CT-P13 …